NVO Jun 2024 116.000 put
| Previous close | 0.3100 |
| Open | 0.3100 |
| Bid | 0.0100 |
| Ask | 1.1400 |
| Strike | 116.00 |
| Expiry date | 2024-06-14 |
| Day's range | 0.3100 - 0.3100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireNovo Nordisk launches national Wegovy® campaign, Power of Wegovy®
Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone.
Investor's Business DailyS&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Intuitive Surgical and Universal Health are all trading in or near buy zones. Medical stocks are often viewed as defensive growth stocks, because their growth is insulated from economic swings due to the government or insurance covering most of the costs. Eli Lilly is in a buy zone while weight-loss drug rival and fellow IBD Leaderboard member Novo Nordisk is setting up.
Investor's Business DailyNetflix Stock Faces Test Of Time As IBD 50 Oil Stock Nears 10-Bagger Status
As a stock's advance gets long in the tooth, shares may still form bases, but late-stage formations carry risks. Netflix stock and Novo Nordisk, two IBD 50 growth stocks, are in late-stage bases. The fourth or fifth bases in a long-term advance are more prone to failure than earlier patterns, mainly because it gets harder to extend gains the longer that shares keep rising.
